NCT07738276: Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
- State
- Not started
- Phase
- Phase 3
- People
- 60 planned
- Started
- 18 Jul 2026
- Primary completion
- 11 Jun 2027
- Arms
- Tirzepatide
- Results
- None posted
- 31 Jul 2026: Trial registered